
Tay Therapeutics in licensing deal with VYNE Therapeutics
Tay Therapeutics Ltd’s exclusive license deal with VYNE Therapeutics Inc. on the oral BET inhibitor, TAY-B2 (now known as VYN201) forsees an upfront...

5 Alarm Bio Ltd raises £500K in seed round
Cambridge Angels, Meltwind, o2h Ventures, SyndicateRoom, as well as other angel investors participated in Five Alarm Bio’s (FAB) seed round with...

Pfizer-Seagen: Acquisition in the works
As announced earlier this week, Pfizer Inc. plans to purchase Seagen for US$43bn. The Boards of Directors of both companies approved the transaction...

Mainz Biomed Partners with Microba Life Sciences
Leveraging a platform for measuring the human gut microbiome to discover and develop novel therapeutics for major diseases, Microba and Mainz Biomed...

Medigene licences CD40L-CD28 costimulatory switch receptor
Medigene has licences the global exclusive rights for CD40L-CD28 costimulatory switch receptor from the Helmholtz Centre Munich. Financial details...